These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

283 related items for PubMed ID: 16740753

  • 1. Which cyclin E prevails as prognostic marker for breast cancer? Results from a retrospective study involving 635 lymph node-negative breast cancer patients.
    Sieuwerts AM, Look MP, Meijer-van Gelder ME, Timmermans M, Trapman AM, Garcia RR, Arnold M, Goedheer AJ, de Weerd V, Portengen H, Klijn JG, Foekens JA.
    Clin Cancer Res; 2006 Jun 01; 12(11 Pt 1):3319-28. PubMed ID: 16740753
    [Abstract] [Full Text] [Related]

  • 2. Increased expression of urokinase-type plasminogen activator mRNA determines adverse prognosis in ErbB2-positive primary breast cancer.
    Urban P, Vuaroqueaux V, Labuhn M, Delorenzi M, Wirapati P, Wight E, Senn HJ, Benz C, Eppenberger U, Eppenberger-Castori S.
    J Clin Oncol; 2006 Sep 10; 24(26):4245-53. PubMed ID: 16963728
    [Abstract] [Full Text] [Related]

  • 3. The prognostic value of polymorphonuclear leukocyte elastase in patients with primary breast cancer.
    Foekens JA, Ries C, Look MP, Gippner-Steppert C, Klijn JG, Jochum M.
    Cancer Res; 2003 Jan 15; 63(2):337-41. PubMed ID: 12543785
    [Abstract] [Full Text] [Related]

  • 4. Mammaglobin is associated with low-grade, steroid receptor-positive breast tumors from postmenopausal patients, and has independent prognostic value for relapse-free survival time.
    Span PN, Waanders E, Manders P, Heuvel JJ, Foekens JA, Watson MA, Beex LV, Sweep FC.
    J Clin Oncol; 2004 Feb 15; 22(4):691-8. PubMed ID: 14966093
    [Abstract] [Full Text] [Related]

  • 5. Identification of a three-gene expression signature of poor-prognosis breast carcinoma.
    Bièche I, Tozlu S, Girault I, Lidereau R.
    Mol Cancer; 2004 Dec 20; 3(1):37. PubMed ID: 15606925
    [Abstract] [Full Text] [Related]

  • 6. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
    Pentheroudakis G, Kalogeras KT, Wirtz RM, Grimani I, Zografos G, Gogas H, Stropp U, Pectasides D, Skarlos D, Hennig G, Samantas E, Bafaloukos D, Papakostas P, Kalofonos HP, Pavlidis N, Fountzilas G.
    Breast Cancer Res Treat; 2009 Jul 20; 116(1):131-43. PubMed ID: 18668363
    [Abstract] [Full Text] [Related]

  • 7. Molecular and biochemical testing in stage III melanoma: multimarker reverse transcriptase-polymerase chain reaction assay of lymph fluid after lymph node dissection and preoperative serum lactate dehydrogenase level.
    Nowecki ZI, Rutkowski P, Kulik J, Siedlecki JA, Ruka W.
    Br J Dermatol; 2008 Sep 20; 159(3):597-605. PubMed ID: 18616789
    [Abstract] [Full Text] [Related]

  • 8. Cyclin E and survival in patients with breast cancer.
    Keyomarsi K, Tucker SL, Buchholz TA, Callister M, Ding Y, Hortobagyi GN, Bedrosian I, Knickerbocker C, Toyofuku W, Lowe M, Herliczek TW, Bacus SS.
    N Engl J Med; 2002 Nov 14; 347(20):1566-75. PubMed ID: 12432043
    [Abstract] [Full Text] [Related]

  • 9. DNA hypermethylation of PITX2 is a marker of poor prognosis in untreated lymph node-negative hormone receptor-positive breast cancer patients.
    Nimmrich I, Sieuwerts AM, Meijer-van Gelder ME, Schwope I, Bolt-de Vries J, Harbeck N, Koenig T, Hartmann O, Kluth A, Dietrich D, Magdolen V, Portengen H, Look MP, Klijn JG, Lesche R, Schmitt M, Maier S, Foekens JA, Martens JW.
    Breast Cancer Res Treat; 2008 Oct 14; 111(3):429-37. PubMed ID: 17965955
    [Abstract] [Full Text] [Related]

  • 10. Expression of cyclins E, A, and B, and prognosis in lymph node-negative breast cancer.
    Kühling H, Alm P, Olsson H, Fernö M, Baldetorp B, Parwaresch R, Rudolph P.
    J Pathol; 2003 Apr 14; 199(4):424-31. PubMed ID: 12635132
    [Abstract] [Full Text] [Related]

  • 11. Cyclin E expression in operable breast cancer quantified using real-time RT-PCR: a comparative study with immunostaining.
    Potemski P, Pluciennik E, Bednarek AK, Kusinska R, Jesionek-Kupnicka D, Pasz-Walczak G, Watala C, Kordek R.
    Jpn J Clin Oncol; 2006 Mar 14; 36(3):142-9. PubMed ID: 16520356
    [Abstract] [Full Text] [Related]

  • 12. Prognostic value of uPA and p53 accumulation measured by quantitative biochemical assays in 1245 primary breast cancer patients: a multicentre study.
    Broët P, Spyratos F, Romain S, Quillien V, Daver A, Ricolleau G, Rallet A, Toulas C, Asselain B.
    Br J Cancer; 1999 May 14; 80(3-4):536-45. PubMed ID: 10408864
    [Abstract] [Full Text] [Related]

  • 13. Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer.
    Ignatiadis M, Xenidis N, Perraki M, Apostolaki S, Politaki E, Kafousi M, Stathopoulos EN, Stathopoulou A, Lianidou E, Chlouverakis G, Sotiriou C, Georgoulias V, Mavroudis D.
    J Clin Oncol; 2007 Nov 20; 25(33):5194-202. PubMed ID: 17954712
    [Abstract] [Full Text] [Related]

  • 14. ATBF1-a messenger RNA expression is correlated with better prognosis in breast cancer.
    Zhang Z, Yamashita H, Toyama T, Sugiura H, Ando Y, Mita K, Hamaguchi M, Kawaguchi M, Miura Y, Iwase H.
    Clin Cancer Res; 2005 Jan 01; 11(1):193-8. PubMed ID: 15671546
    [Abstract] [Full Text] [Related]

  • 15. How ADAM-9 and ADAM-11 differentially from estrogen receptor predict response to tamoxifen treatment in patients with recurrent breast cancer: a retrospective study.
    Sieuwerts AM, Meijer-van Gelder ME, Timmermans M, Trapman AM, Garcia RR, Arnold M, Goedheer AJ, Portengen H, Klijn JG, Foekens JA.
    Clin Cancer Res; 2005 Oct 15; 11(20):7311-21. PubMed ID: 16243802
    [Abstract] [Full Text] [Related]

  • 16. Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer.
    Foekens JA, Atkins D, Zhang Y, Sweep FC, Harbeck N, Paradiso A, Cufer T, Sieuwerts AM, Talantov D, Span PN, Tjan-Heijnen VC, Zito AF, Specht K, Hoefler H, Golouh R, Schittulli F, Schmitt M, Beex LV, Klijn JG, Wang Y.
    J Clin Oncol; 2006 Apr 10; 24(11):1665-71. PubMed ID: 16505412
    [Abstract] [Full Text] [Related]

  • 17. Prognostic relevance of cyclin E expression in operable breast cancer.
    Potemski P, Kusińska R, Pasz-Walczak G, Piekarski JH, Watała C, Płuciennik E, Bednarek AK, Kordek R.
    Med Sci Monit; 2009 Feb 10; 15(2):MT34-40. PubMed ID: 19179977
    [Abstract] [Full Text] [Related]

  • 18. Survivin expression predicts early recurrence in early-stage breast cancer.
    Yamashita S, Masuda Y, Kurizaki T, Haga Y, Murayama T, Ikei S, Kamei M, Takeno S, Kawahara K.
    Anticancer Res; 2007 Feb 10; 27(4C):2803-8. PubMed ID: 17695451
    [Abstract] [Full Text] [Related]

  • 19. Validation of 70-gene prognosis signature in node-negative breast cancer.
    Bueno-de-Mesquita JM, Linn SC, Keijzer R, Wesseling J, Nuyten DS, van Krimpen C, Meijers C, de Graaf PW, Bos MM, Hart AA, Rutgers EJ, Peterse JL, Halfwerk H, de Groot R, Pronk A, Floore AN, Glas AM, Van't Veer LJ, van de Vijver MJ.
    Breast Cancer Res Treat; 2009 Oct 10; 117(3):483-95. PubMed ID: 18819002
    [Abstract] [Full Text] [Related]

  • 20. HOXB13-to-IL17BR expression ratio is related with tumor aggressiveness and response to tamoxifen of recurrent breast cancer: a retrospective study.
    Jansen MP, Sieuwerts AM, Look MP, Ritstier K, Meijer-van Gelder ME, van Staveren IL, Klijn JG, Foekens JA, Berns EM.
    J Clin Oncol; 2007 Feb 20; 25(6):662-8. PubMed ID: 17308270
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.